Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study

Urol Int. 2009;83(1):49-54. doi: 10.1159/000224868. Epub 2009 Jul 27.

Abstract

Introduction: To investigate the incidence of ejaculatory disorders caused by naftopidil and tamsulosin in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

Materials and methods: Ninety-five patients with LUTS/BPH who had International Prostate Symptom Scores (IPSS) of 8 or more were randomly assigned to receive naftopidil (50 mg/day, n = 48) or tamsulosin (0.2 mg/day, n = 47). Before and 12 weeks after treatment, a questionnaire was used to evaluate ejaculation.

Results: Among men who had sexual activity during the 12 weeks, the proportion who reported an abnormal feeling on ejaculation was higher in the tamsulosin group (16.7%) than in the naftopidil group (7.4%), although the difference was not significant (p = 0.402). The proportion of men who reported reduced ejaculatory volume after treatment was significantly higher in the tamsulosin group (96.0%) than in the naftopidil group (73.1%, p = 0.0496). On the other hand, the improvements in IPSS and the quality of life index were significantly higher in the tamsulosin group than in the naftopidil group.

Conclusions: Tamsulosin may cause a higher incidence of ejaculatory disorders than naftopidil, although the efficacy of 0.2 mg tamsulosin may be better than that of 50 mg naftopidil.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adrenergic alpha-Antagonists / adverse effects*
  • Adrenergic alpha-Antagonists / therapeutic use
  • Aged
  • Ejaculation / drug effects*
  • Humans
  • Male
  • Middle Aged
  • Naphthalenes / adverse effects*
  • Naphthalenes / therapeutic use
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use
  • Prostatic Hyperplasia / complications*
  • Sulfonamides / adverse effects*
  • Sulfonamides / therapeutic use
  • Tamsulosin
  • Urination Disorders / drug therapy*
  • Urination Disorders / etiology

Substances

  • Adrenergic alpha-Antagonists
  • Naphthalenes
  • Piperazines
  • Sulfonamides
  • Tamsulosin
  • naftopidil